中国医药
中國醫藥
중국의약
CHINA MEDICINE
2010年
9期
819-820
,共2页
程功%乔媛%姚晓伟%杨军录%寿锡凌
程功%喬媛%姚曉偉%楊軍錄%壽錫凌
정공%교원%요효위%양군록%수석릉
冠状动脉疾病%阿司匹林%丹参注射液
冠狀動脈疾病%阿司匹林%丹參註射液
관상동맥질병%아사필림%단삼주사액
Coronary artery disease%Aspirin%Danshen injection
目的 探讨复方丹参注射液单用及联合阿司匹林对阿司匹林抵抗(AR)患者血小板聚集率的影响.方法 筛选出AR及阿司匹林半抵抗(ASR)患者共52例,完全随机分为2组,单用复方丹参注射液组和阿司匹林+复方丹参注射液组.干预2周后复查血小板聚集率.结果 单用复方丹参注射液组干预前后二磷酸腺苷(ADP)和花生四烯酸(AA)诱导的血小板聚集率分别为(73.8±3.9)%、(68.6±3.7)%、(22.8±2.4)%、(18.5±2.3)%;阿司匹林+复方丹参注射液组分别为(74.2±3.8)%、(61.3±4.2)%、(23.1±2.6)%、(12.7±2.2)%.2组干预后各指标均较干预前有下降,差异有统计学意义(P＜0.05或P＜0.01);阿司匹林+复方丹参注射液组干预后各指标较单用复方丹参注射液组下降,差异亦有统计学意义(P＜0.05).结论 复方丹参注射液单用及联合阿司匹林治疗均可降低AR患者血小板聚集率,但联合应用效果更佳.
目的 探討複方丹參註射液單用及聯閤阿司匹林對阿司匹林牴抗(AR)患者血小闆聚集率的影響.方法 篩選齣AR及阿司匹林半牴抗(ASR)患者共52例,完全隨機分為2組,單用複方丹參註射液組和阿司匹林+複方丹參註射液組.榦預2週後複查血小闆聚集率.結果 單用複方丹參註射液組榦預前後二燐痠腺苷(ADP)和花生四烯痠(AA)誘導的血小闆聚集率分彆為(73.8±3.9)%、(68.6±3.7)%、(22.8±2.4)%、(18.5±2.3)%;阿司匹林+複方丹參註射液組分彆為(74.2±3.8)%、(61.3±4.2)%、(23.1±2.6)%、(12.7±2.2)%.2組榦預後各指標均較榦預前有下降,差異有統計學意義(P＜0.05或P＜0.01);阿司匹林+複方丹參註射液組榦預後各指標較單用複方丹參註射液組下降,差異亦有統計學意義(P＜0.05).結論 複方丹參註射液單用及聯閤阿司匹林治療均可降低AR患者血小闆聚集率,但聯閤應用效果更佳.
목적 탐토복방단삼주사액단용급연합아사필림대아사필림저항(AR)환자혈소판취집솔적영향.방법 사선출AR급아사필림반저항(ASR)환자공52례,완전수궤분위2조,단용복방단삼주사액조화아사필림+복방단삼주사액조.간예2주후복사혈소판취집솔.결과 단용복방단삼주사액조간예전후이린산선감(ADP)화화생사희산(AA)유도적혈소판취집솔분별위(73.8±3.9)%、(68.6±3.7)%、(22.8±2.4)%、(18.5±2.3)%;아사필림+복방단삼주사액조분별위(74.2±3.8)%、(61.3±4.2)%、(23.1±2.6)%、(12.7±2.2)%.2조간예후각지표균교간예전유하강,차이유통계학의의(P＜0.05혹P＜0.01);아사필림+복방단삼주사액조간예후각지표교단용복방단삼주사액조하강,차이역유통계학의의(P＜0.05).결론 복방단삼주사액단용급연합아사필림치료균가강저AR환자혈소판취집솔,단연합응용효과경가.
Objective To investigate the effects of the compound Danshen injection and combined with aspirin on platelet aggregation ratio in the patients with aspirin resistance. Methods A total of 52 patients with aspirin resistance and semiresistance were screened for the observation and were randomly assigned to two groups. The first group was administered intravenously with the compound Danshen combined with aspirin, the other group was treated intravenously with compound Danshen only. Two weeks later, all were retested the platelet aggregation ratio. Results The platelet aggregation ratio induced by ADP and AA was (73.8 ±3.9)%, (68.6±3.7)%, (12.7±2.2)% , (18.5 ±2. 3)% ; the platelet aggregation ratio of patients treated with compound Danshen injection and combined with aspirin was (74.2 ±3.8)%, (61.3 ±4.2)%, (23. 1 ±2.6)%, (12.7 ±2.2)%. Both of them had a significantly decrease in various indexes (P <0.05 or P <0.01) ; moreover, the platelet aggregation ratio of patients treated with compound Danshen injection and combined with aspirin has a lower level than that of patients treated with compound Danshen only (P <0. 05 ) . Conclusions Both compound Danshen injection alone and combination with aspirin therapy may reduce platelet aggregation in patients with aspirin resistance.
